Customization of In Vivo Transfection Systems for Targeting Tumor Cells
It is well known that primary and secondary cancers in different tissues and organs have different tissue and cellular characteristics. Using genetic engineering techniques such as RNA interference or Cas9 system to conduct functional studies at the gene level In Vivo requires an In Vivo transfection system that can accurately target tumor tissues and be taken up by tumor cells to play a role in the cells. This system is used to help researchers overcome various challenges encountered during In Vivo transfection:
- Different tissue tumors have different barriers to In Vivo transfection, and a suitable In Vivo transfection system cannot be found;
- In Vivo transfection efficiency is low;
- The In Vivo transfection system causes stress to the body itself and affects the experimental results;
- During In Vivo transfection, the contained nucleic acid substances are easily leaked and destroyed by the In Vivo environment and enzymes;
- The payload of the In Vivo transfection system is low, and it is difficult to achieve the desired effect;
- Etc…
Figure 1. Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma.(Vaughan HJ, et al.;2022)
Our Advantage:
- We can provide In Vivo transfection systems targeting target tissues and cells to achieve efficient transfection
- The system can target multiple targets and improve targeting accuracy
- The In Vivo transfection system has low toxicity to the body and is safe to use
- In Vivo transfection system vectors can protect nucleic acids from being degraded during In Vivo delivery
- Allows experimental animals to produce a sustained knockout effect after a single injection
- The system has a high load and can complete the transfection requirements of different doses
- Professional design and service team to provide you with reliable service and technical support
- Timely feedback of technical reports
Our Services:
In Vivo Transfection Services for Colorectal Cancer
In Vivo Transfection Services for Endometrial Cancer
In Vivo Transfection Services for Gastrointestinal Stromal Tumor
In Vivo Transfection Services for Glioblastoma
In Vivo Transfection Services for Head & Neck Cancer
In Vivo Transfection Services for Hodgkin's Lymphoma
In Vivo Transfection Services for Laryngeal Cancer
In Vivo Transfection Services for Liposarcoma
In Vivo Transfection Services for Multiple Myeloma
In Vivo Transfection Services for Non-hodgkin Lymphoma B cell
In Vivo Transfection Services for Non-Hodgkin Lymphoma T cell
In Vivo Transfection Services for Non-small cell lung cancer
In Vivo Transfection Services for Osteosarcoma
In Vivo Transfection Services for Ovarian Cancer
In Vivo Transfection Services for Pancreatic Cancer
In Vivo Transfection Services for Prostate Cancer
In Vivo Transfection Services for Renal Cancer
In Vivo Transfection Services for Small Cell Lung Cancer
In Vivo Transfection Services for Thyroid Cancer
In Vivo Transfection Services for Lung Cancer
In Vivo Transfection Services for Liver Cancer
In Vivo Transfection Services for Breast Cancer
In Vivo Transfection Services for Stomach Cancer
In Vivo Transfection Services for Cervical Cancer
In Vivo Transfection Services for Chronic Lymphocytic Leukemia
In Vivo Transfection Services for Acute lymphocytic leukemia
In Vivo Transfection Services for Acute myelogenous leukemia
In Vivo Transfection Services for Astrocytoma
In Vivo Transfection Services for Bladder Cancer
In Vivo Transfection Services for Lymphangioma
In Vivo Transfection Services for Brain Cancer
CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved. If you can't find a perfect In Vivo transfection system, you can contact us. We can provide one-to-one personal customization service.
Reference
- Vaughan HJ, et al.; Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma. Sci Adv. 2022, 8(29):eabo6406.
* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.
Online Inquiry
Please submit a detailed description of your project. Our industry-leading scientists will review the information provided as soon as possible. You can also send emails directly to for inquiries.